
    
      This is a special drug use surveillance on long-term use of alogliptin with a 1-year
      (12-month) observational period, designed to investigate the safety and efficacy of long-term
      combination therapy with alogliptin and thiazolidinediones in patients with type 2 diabetes
      mellitus in a routine clinical setting.

      Participants will be patients with type 2 diabetes mellitus who failed to respond adequately
      to treatment with thiazolidinediones in addition to diet therapy and exercise therapy. The
      planned sample size is 1,000 subjects.

      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
    
  